anti-inflammatory property
[용어속성] Term
Utility of NO and H2S donating platforms in managing COVID-19: Rationale and promise
Review article
[키워드] addition
anti-inflammatory property
Antiviral
antiviral action
antiviral therapies
changes
Complication
COVID-19
COVID-19 pandemic
current
Cytokine storm
death
direct infection
endothelial damage
Endothelium
Evidence
function
host cell
Hydrogen sulfide
Hyperinflammatory
Infection
Inflammation
iNOS
limit
nitric oxide
occur
platform
Protective
pulmonary damage
rationale
reduce
Respiratory failure
Respiratory system
resulting
SARS-CoV-2
signaling molecule
supportive therapy
therapeutic approaches
thrombosis
Treatment
Vascular
vasculature
viral infection
viral infections
[DOI] 10.1016/j.niox.2022.08.003 [Article Type] Review article
[DOI] 10.1016/j.niox.2022.08.003 [Article Type] Review article
Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19
Article
Published on
Journal: American journal of physiology. Lung cellular and [Category] COVID19(2023년), SARS, 치료제,
Journal: American journal of physiology. Lung cellular and [Category] COVID19(2023년), SARS, 치료제,
[키워드] ACE-2
ACE2
addition
airway
alveolar
angiotensin-converting enzyme 2
anti-inflammatory effect
Anti-inflammatory effects
anti-inflammatory property
antioxidant
Antiviral
Antiviral effect
antiviral effects
binding
cell entry
cleavage
cleave
Concentration
COVID-19
cysteamine
decrease
determine
disrupt
drug
drugs
Effect
effective
functional
hamster
hemorrhage
in vivo
infected with SARS-CoV-2
Inflammation
inhibit
Injury
intraperitoneally
limit
lung
Lung inflammation
Lung injury
mechanism
neutrophilic
oxidative stress
pseudovirus
redox status
reporter
SARS-2-S
SARS-CoV-2
SARS-CoV-2 cell
SARS-CoV-2 spike glycoprotein
SARS-CoV-2 viruses
significantly
tested
thiol drugs.
thiol group
viral infection
virus infection
[DOI] 10.1152/ajplung.00136.2022 PMC 바로가기
[DOI] 10.1152/ajplung.00136.2022 PMC 바로가기
Chemerin plasma levels are increased in COVID-19 patients and are an independent risk factor of mortality
Article
[키워드] activity
acute respiratory distress
Admission
Analysis
analyzed
anti-inflammatory property
ARDS
Belgium
Biomarker
blood cell
blood sample
C-reactive protein
chemerin
chemotactic
ChemR23
Clinical practice
CMKLR1
collected
Concentration
correlated
COVID-19
COVID-19 patient
COVID-19 patients
death
Deceased
demonstrated
disease
evaluate
evaluated
expression
Extracellular
flow cytometry
healthy control
ICU
ICU patient
identify
IHC
immunohistochemistry
Increased
independent risk factor
Inflammatory biomarker
inflammatory conditions
intensive care
Lung pathology
lung tissue
marker
mechanism
Mortality
Necrosis
Patient
plasma
predict
prediction
Prognostic value
Protein
severity
significantly higher
smooth muscle cell
subtype
survival
survivor
syndrome
Viral pneumonia
[DOI] 10.3389/fimmu.2022.941663 PMC 바로가기
[DOI] 10.3389/fimmu.2022.941663 PMC 바로가기
Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019
2019년 코로나바이러스로 인한 급성호흡곤란증후군에 대한 중간엽 기질세포 치료
Article
[키워드] 95% CI
95% confidence interval
acute lung injury
acute respiratory distress
acute respiratory distress syndrome
Allogeneic
anti-inflammatory property
ARDS
C-reactive protein
case sery
cells
clinical outcomes
coronavirus disease
COVID-19
COVID-19-associated ARDS
declined
discharged
dose
eligible
follow-up period
high mortality
hospital
Inflammatory cytokine
intensive care
Kidney injury
less
liver
Lung disease
mechanical ventilation
mechanically ventilated
median time
Mesenchymal stromal cell
Mesenchymal stromal cells
moderate
MSC
MSCs
nine
Patient
patients
patients died
remained
Remestemcel-L
requiring supplemental oxygen
resulting
Safe
shown
significantly
stromal cell
syndrome
therapy
treat
treated
were excluded
[DOI] 10.1016/j.jcyt.2022.03.006 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.jcyt.2022.03.006 PMC 바로가기 [Article Type] Article
Clinical progress in MSC-based therapies for the management of severe COVID-19
Mini review
[키워드] MB-MSCs
Menstrual blood-derived Mesenchymal Stromal Cells
3-dioxygenase
ACE2angiotensin converting enzyme 2
acute graft-versus-host disease
acute respiratory distress syndrome
Adipose Tissue derived Mesenchymal Stromal Cells
admadministration
administration
alanine aminotransferase
Allo-MSCsAllogeneic Mesenchymal Stromal Cells
Alloallogeneic
Allogeneic
Allogeneic Mesenchymal Stromal Cells
ALTalanine aminotransferase
angiotensin converting enzyme 2
anti-inflammatory property
ARDS
ARDSacute respiratory distress syndrome
Aspartate aminotransferase
ASTaspartate aminotransferase
AT-MSCsAdipose Tissue derived Mesenchymal Stromal Cells
AT2type 2 alveolar cells of the lungs
BALFbronchoalveolar lavage fluid
BM-MSCsbone marrow derived MSCs
body weight
bone marrow derived MSCs
Bronchoalveolar lavage fluid
bwBody weight
C-reactive protein
cAMPcyclic adenosine monophosphate
candidate
CDcluster of differentiation
Cell
clinical
clinical trial
cluster of differentiation
complex
conducted
Coronavirus disease 2019
coronavirus disease of 2019
COVID-19
COVID-19Coronavirus disease of 2019
CRPC-reactive protein
cyclic adenosine monophosphate
cytokine
Daewoong Pharmaceutical’s Mesenchymal Stromal Cells
DCsdendritic cells
dendritic cells
driven by
DSCsPlacenta-derived decidua stromal cells
DW-MSCsDaewoong Pharmaceutical’s Mesenchymal Stromal Cells
EVsextracellular vesicles
Extracellular vesicles
Fas ligands
Fas-LFas ligands
FDAFood and Drug Administration
FGFfibroblast growth factor
fibroblast growth factor
Food and Drug Administration
forkhead box P3 +
FOXP3 +forkhead box P3 +
G-CSFgranulocyte colony-stimulating factor
Gal-1galectin-1
Gal-3galectin-3
Gal-9galectin-9
galectin-1
galectin-3
Galectin-9
GM-CSFgranulocyte macrophage-colony stimulating factor
granulocyte colony-stimulating factor
granulocyte macrophage-colony stimulating factor
growth factor
GvHDacute graft-versus-host disease
HB-AT-MSCsHope Biosciences autologous adipose-derived mesenchymal stromal cells
HdHigh dose
hepatocyte growth factor
HGFhepatocyte growth factor
High dose
HLAHuman leukocyte antigen
Hope Biosciences autologous adipose-derived mesenchymal stromal cells
human leukocyte antigen
ICUIntensive Care Unit
IDOIndoleamine 2
IFN-γinterferon-γ
IL-10interleukin-10
IL-1interleukin-1
IL-1βinterleukin-1β
IL-2 receptor
IL-2interleukin-2
IL-2RIL-2 receptor
IL-4interleukin-4
IL-6interleukin-6
IL-7Interleukin 7
IL-7interleukin-7
IL-8interleukin 8
IL-9interleukin
IL1-αinterleukin 1-α
IL1-βinterleukin 1-β
IL1RaInterleukin-1 receptor antagonist
immune dysregulation
immunological
immunomodulatory
IMVInvasive mechanical ventilation
Indoleamine 2
inducible protein 10
inflammatory process
inhalation
INHinhalation
intensive care unit
interferon-γ
interleukin
interleukin 1-α
interleukin 1-β
Interleukin 7
interleukin 8
interleukin-1
Interleukin-1 receptor antagonist
interleukin-10
interleukin-1β
interleukin-2
Interleukin-4
interleukin-6
interleukin-7
intravenous
Invasive mechanical ventilation
IP-10inducible protein 10
IVintravenous
keratinocyte growth factor
KGFkeratinocyte growth factor
lactate dehydrogenase
LDHlactate dehydrogenase
LdLow dose
lipopolysaccharide
low dose
LPSlipopolysaccharide
major histocompatibility complex
management
MAPKmitogen-activated protein kinase
MCP-1monocyte chemoattractant protein-1
Mesenchymal stromal cell
Mesenchymal stromal cells
MHCMajor Histocompatibility Complex
microRNA
miRNAmicroRNA
MIS-Cmultisystem inflammatory syndrome in children
mitogen-activated protein kinase
monocyte chemoattractant protein-1
MSCs
MSCsmesenchymal stromal cells
multisystem inflammatory syndrome in children
nanovesicles
National Institutes of Health
natural
NETsNeutrophil Extracellular Traps
Neutrophil extracellular traps
NF-κBnuclear factor-kappa B
NIHNational Institutes of Health
nitric oxide
NKnatural
NONitric Oxide
nuclear factor-kappa B
NVsnanovesicles
occur
PD-1programmed cell death protein 1
PD-L1programmed death ligand-1
PGE2prostaglandin E2
pharmacological management
PL-MSCsPlacental-derived Mesenchymal Stromal Cells
Placenta-derived decidua stromal cells
placental expanded
Placental-derived Mesenchymal Stromal Cells
PLX-PADplacental expanded
programmed cell death protein 1
programmed death ligand-1
prostaglandin E2
protein spike
public health
reactive oxygen species
Regulatory T cell
Respiratory failure
RFrespiratory failure
ROSreactive oxygen species
SARS-CoV-2severe acute respiratory syndrome coronavirus 2
Secretome
severe acute respiratory syndrome coronavirus 2
severe COVID-19
Severe respiratory distress
signal transducer activators of transcription-3
Sprotein spike
STAT3signal transducer activators of transcription-3
syndrome
TGF-β1transforming growth factor-β1
TGFtransforming growth factor
the cytokine storm
the disease
therapeutic
therapy
TLRtoll-like receptors
TNF-α-stimulating gene 6
TNF-αtumor necrosis factor-α
TNFTumor Necrosis Factor
Toll-like receptors
transforming growth factor
transforming growth factor-β1
treat
Tregregulatory T cell
TSG-6TNF-α-stimulating gene 6
tumor necrosis factor
tumor necrosis factor-α
type 2 alveolar cells of the lungs
UC-MSCsumbilical cord derived MSCs
umbilical cord derived MSCs
vascular endothelial growth factor
VEGFvascular endothelial growth factor
Wharton’s Jelly–derived Mesenchymal Stromal Cells
WJ-MSCsWharton’s Jelly–derived Mesenchymal Stromal Cells
[DOI] 10.1016/j.cytogfr.2022.07.002 [Article Type] Mini review
[DOI] 10.1016/j.cytogfr.2022.07.002 [Article Type] Mini review
The SARS-CoV-2 helicase as a target for antiviral therapy: Identification of potential small molecule inhibitors by in silico modelling
항바이러스 치료의 표적으로서의 SARS-CoV-2 헬리카제: in silico 모델링을 통한 잠재적인 소분자 억제제 식별
Article
Published on
Journal: Journal of molecular graphics & modelling [Category] COVID19(2023년), SARS, 변종, 진단, 치료제,
Journal: Journal of molecular graphics & modelling [Category] COVID19(2023년), SARS, 변종, 진단, 치료제,
[키워드] Acetylcysteine
active site
acute respiratory syndrome
addition
anti-inflammatory property
Antiviral
antiviral activity
antiviral therapeutics
antivirals
binding free energy
clavulanic acid
Compound
coronavirus
coronavirus disease
COVID-19
DHX9
DNA
DNA2
expected
Fatty acid
fatty acids
free energies
Helicase
Hepatitis
hepatitis C
highlighting
identification
identify
in silico
include
inhibitor
inhibitory activity
initial
lead
leads
Ligand
MERS-CoV
molecular dynamics
Molecular dynamics simulation
molecular dynamics simulations
non-structural protein
nsp13
nucleoside
performed
reported
Research
respiratory
SARS-CoV
SARS-CoV-2
SARS-CoV-2 nsp13
selected
sequence
Severe acute respiratory syndrome
small molecule inhibitor
specific inhibitor
specific inhibitors
strain
structural homology
structural proteins
Structure
structures
synthetic
the SARS-CoV-2
utilised
Vaccine
variant
was performed
were used
[DOI] 10.1016/j.jmgm.2022.108193 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.jmgm.2022.108193 PMC 바로가기 [Article Type] Article
Cyanidin-3-O-glucoside and Peonidin-3-O-glucoside-Rich Fraction of Black Rice Germ and Bran Suppresses Inflammatory Responses from SARS-CoV-2 Spike Glycoprotein S1-Induction In Vitro in A549 Lung Cells and THP-1 Macrophages via Inhibition of the NLRP3 Inflammasome Pathway
시아니딘-3-O-글루코사이드 및 피오니딘-3-O-글루코사이드-풍부 검정 쌀 배아 및 겨 분획은 A549 폐 세포 및 THP-1 대식세포에서 SARS-CoV-2 스파이크 당단백질 S1-유도 시험관 내 염증 반응을 억제합니다 NLRP3 Inflammasome 경로의 억제
Article
[키워드] A549
Activation
anthocyanin
anthocyanins
Anti-inflammation
anti-inflammatory property
ASC
attenuate
benefit
black
black rice
bran
C3G
Cell
cell lines
Concentration
counteraction
COVID-19
COVID-19 infection
cytokine secretion
dose-dependent manner
downregulation
Effect
exhibited
exposure to
fraction
functional
functional food
Gene Expression
Germ
Health
health benefits
HPLC
IL-18
IL-1β
IL-6
immune cells
in vitro model
Inflammasome
Inflammation
Inflammatory
Inflammatory response
Inflammatory responses
inhibition
innate immune cell
Innate immune cells
long-COVID
lung tissue
Macrophage
macrophages
mechanism
NF-kB
NLRP3
NLRP3 inflammasome
P3G
pathway
post-acute COVID
protective effect
Protective effects
Protein
protein level
protein levels
reported
response
responsible
Rice
S1 subunit
SARS-CoV-2
spike
spike glycoprotein
spike glycoprotein S1.
THP-1
treated
was determined
[DOI] 10.3390/nu14132738 PMC 바로가기 [Article Type] Article
[DOI] 10.3390/nu14132738 PMC 바로가기 [Article Type] Article
Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19)
Randomized Controlled Trial
[키워드] 95% CI
adverse event
age
anti-inflammatory property
Anti-viral
ARMS
assigned
chose
clinically
coronavirus disease
COVID-19
demonstrated
determine
double-blind
Effect
FDA
female
group
Hospitalization
incidence
IND
measure
Mild
mitigate
one patient
outcome
Outpatient
participant
Patient
Phase 2 study
Placebo
placebo-controlled
Pneumonia
primary outcome measure
randomization
Randomly
receive
recruited
resveratrol
single dose
small sample size
statistically
Symptom
treated
Treatment
Trial
Vitamin D3
was determined
was used
[DOI] 10.1038/s41598-022-13920-9 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1038/s41598-022-13920-9 PMC 바로가기 [Article Type] Randomized Controlled Trial
Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19
SARS-CoV-2에 대한 아프로티닌 치료: 중등도 COVID-19에 대한 범프로테아제 억제제의 안전성과 효능을 평가하기 위한 무작위 3상 연구
Clinical Trial
Published on
Journal: European Journal of Clinical Investigation [Category] COVID19(2023년), SARS, 임상, 치료제,
Journal: European Journal of Clinical Investigation [Category] COVID19(2023년), SARS, 임상, 치료제,
[키워드] ACE2
addition
administration
Adverse reaction
Adverse reactions
anti-inflammatory properties
anti-inflammatory property
antiviral drug
antivirus
Aprotinin
cleave
Clinical outcome
clinical trial
Composite
Contact
COVID-19
death
discharge
double-blind
Efficacy
evaluate
follow-up period
furin
had no
hospital
Hospital admission
Hospital stay
Hospitalization
hospitalized patient
hospitalized patients
host protease
host proteases
human respiratory viruses
ICU admission
IMPROVE
incidence
inhalation therapy
inhibiting
inhibitor
Innate immunity
less
mechanism
Moderate COVID-19
multicentre
outcome
oxygen
Oxygen therapy
parameter
patients with COVID-19
performed
placebo group
Pneumonia
profiles
Protease inhibitor
Randomized
randomized trial
required
respiratory viruses
resulting
Safe
Safety
SARS-CoV-2
SARS-CoV-2 virus
secondary endpoint
Secondary endpoints
Side effects
significant difference
significant differences
Spanish
Spike protein
standard treatment
the placebo group
Treatment
with COVID-19
[DOI] 10.1111/eci.13776 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1111/eci.13776 PMC 바로가기 [Article Type] Clinical Trial